ELI LILLY & Co (LLY) stock
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 19/3025% above fair value
$1382.75−32.80 (-2.32%)
Close on Nov 18, 2026Market cap $1.30TP/E 44.9Yield 0.45%
Eli Lilly revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Eli Lilly's revenue for the twelve months ending Sep 30, 2026 was $86.46B, up 45.5% year over year. For fiscal 2025 it was $65.18B, up 44.7% from the year before. Over ten years it grew 12.6% a year on average. The highest annual figure on record is $65.18B in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $65.18B | +44.7% |
| FY2024 | Dec 31, 2024 | $45.04B | +32.0% |
| FY2023 | Dec 31, 2023 | $34.12B | +19.6% |
| FY2022 | Dec 31, 2022 | $28.54B | +0.8% |
| FY2021 | Dec 31, 2021 | $28.32B | +15.4% |
| FY2020 | Dec 31, 2020 | $24.54B | +9.9% |
| FY2019 | Dec 31, 2019 | $22.32B | +3.8% |
| FY2018 | Dec 31, 2018 | $21.49B | +7.6% |
| FY2017 | Dec 31, 2017 | $19.97B | -5.9% |
| FY2016 | Dec 31, 2016 | $21.22B | +6.3% |
| FY2015 | Dec 31, 2015 | $19.96B | +1.7% |
| FY2014 | Dec 31, 2014 | $19.62B | -15.1% |
| FY2013 | Dec 31, 2013 | $23.11B | +2.3% |
| FY2012 | Dec 31, 2012 | $22.60B | -6.9% |
| FY2011 | Dec 31, 2011 | $24.29B | +5.2% |
| FY2010 | Dec 31, 2010 | $23.08B | +5.7% |
| FY2009 | Dec 31, 2009 | $21.84B | +7.2% |
| FY2008 | Dec 31, 2008 | $20.37B | +9.3% |
| FY2007 | Dec 31, 2007 | $18.63B | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $24.40B | +38.6% |
| Q2 FY2026 | Jun 30, 2026 | $22.97B | +47.7% |
| Q1 FY2026 | Mar 31, 2026 | $19.80B | +55.5% |
| Q4 FY2025 | Dec 31, 2025 | $19.29B | +42.6% |
| Q3 FY2025 | Sep 30, 2025 | $17.60B | +53.9% |
| Q2 FY2025 | Jun 30, 2025 | $15.56B | +37.6% |
| Q1 FY2025 | Mar 31, 2025 | $12.73B | +45.2% |
| Q4 FY2024 | Dec 31, 2024 | $13.53B | +44.7% |
| Q3 FY2024 | Sep 30, 2024 | $11.44B | +20.4% |
| Q2 FY2024 | Jun 30, 2024 | $11.30B | +36.0% |
| Q1 FY2024 | Mar 31, 2024 | $8.77B | +26.0% |
| Q4 FY2023 | Dec 31, 2023 | $9.35B | +28.1% |
| Q3 FY2023 | Sep 30, 2023 | $9.50B | +36.8% |
| Q2 FY2023 | Jun 30, 2023 | $8.31B | +28.1% |
| Q1 FY2023 | Mar 31, 2023 | $6.96B | -10.9% |
| Q4 FY2022 | Dec 31, 2022 | $7.30B | -8.7% |
| Q3 FY2022 | Sep 30, 2022 | $6.94B | +2.5% |
| Q2 FY2022 | Jun 30, 2022 | $6.49B | -3.7% |
| Q1 FY2022 | Mar 31, 2022 | $7.81B | +14.8% |
| Q4 FY2021 | Dec 31, 2021 | $8.00B | +7.5% |
| Q3 FY2021 | Sep 30, 2021 | $6.77B | +18.0% |
| Q2 FY2021 | Jun 30, 2021 | $6.74B | +22.6% |
| Q1 FY2021 | Mar 31, 2021 | $6.81B | +16.1% |
| Q4 FY2020 | Dec 31, 2020 | $7.44B | +21.7% |
| Q3 FY2020 | Sep 30, 2020 | $5.74B | +4.8% |
| Q2 FY2020 | Jun 30, 2020 | $5.50B | -2.4% |
| Q1 FY2020 | Mar 31, 2020 | $5.86B | +15.1% |
| Q4 FY2019 | Dec 31, 2019 | $6.11B | +8.5% |
| Q3 FY2019 | Sep 30, 2019 | $5.48B | +3.2% |
| Q2 FY2019 | Jun 30, 2019 | $5.64B | +0.9% |
| Q1 FY2019 | Mar 31, 2019 | $5.09B | +2.6% |
| Q4 FY2018 | Dec 31, 2018 | $5.64B | -8.5% |
| Q3 FY2018 | Sep 30, 2018 | $5.31B | -6.2% |
| Q2 FY2018 | Jun 30, 2018 | $5.59B | -4.1% |
| Q1 FY2018 | Mar 31, 2018 | $4.96B | -5.1% |
| Q4 FY2017 | Dec 31, 2017 | $6.16B | +6.9% |
| Q3 FY2017 | Sep 30, 2017 | $5.66B | – |
| Q2 FY2017 | Jun 30, 2017 | $5.82B | – |
| Q1 FY2017 | Mar 31, 2017 | $5.23B | – |
| Q4 FY2016 | Dec 31, 2016 | $5.76B | – |
See a number that looks wrong?